Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma has secured a promising financial future through a licensing deal with Vetbiolix for the veterinary drug Piclidenoson, aimed at treating osteoarthritis in pets, projecting income of $325 million over the next decade. This agreement follows a successful clinical trial in dogs and taps into a growing multi-billion-dollar companion animal arthritis market. Can-Fite is set to receive a 15% royalty on global sales, with the drug potentially capturing 6% of the market by 2034.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
